Differential Expression of LEF1 Isoforms in Adult Lymphoid and Myeloid Malignancies

Basit Öğe Kaydı
dc.contributor.authorFırtına, S.
dc.contributor.authorÖzden, H.N.
dc.contributor.authorErbilgin, Y.
dc.contributor.authorHaznedaroğlu, İ.
dc.contributor.authorSayitoğlu, M.
dc.date.accessioned2024-05-19T14:33:18Z
dc.date.available2024-05-19T14:33:18Z
dc.date.issued2021
dc.departmentİstinye Üniversitesien_US
dc.description.abstractObjective: Lymphoid enhancer-binding factor-1 (LEF1) is one of the key regulators of lymphocyte proliferation and its aberrant expression is a prognostic factor for lymphoid or myeloid malignan-cies. In this study, we focused on the expression of LEF1 isoforms in several hematological malignancies and found tissue-specific differential expression for the full-length (FL)-LEF1 gene and its tumor suppressor (?LEF1) variant. Material and Method: Fifty-three leukemia/lymphoma patients were included in this study. Diagnostic samples of “lymphoid group” patients: Chronic Lymphoblastic Leukemia (CLL) (n=10), B-cell Acute Lymphoblastic Leukemia (B-ALL) (n=9) and “myeloid group” patients: Chronic Myeloblastic Leukemia (CML) (n=12), Acute Myeloid Leukemia (AML) (n=13), and Multiple Myeloma (MM) (n=9) were studied. Healthy bone marrow, peripheral blood cells, and CD34 positive cells were used as controls. Total (T) and FL-LEF1 transcript levels were examined by using quantitative re-al-time polymerase chain reaction (qRT-PCR). T and FL-LEF1 mRNA ratios were also evaluated for calculation of ?LEF1. Results: LEF1 levels were significantly high in lymphoid malignan-cies, but MM and AML patients have decreased LEF1 levels. Although CLL patients have high FL-LEF1 levels, the ratio of the T/FL levels was significantly decreased. Conclusion: LEF1 is a proliferation factor for lymphocytes and not only its differential overexpression but also the ratio of T/FL iso-forms seem to accompany leukemia progress. © 2021, Istanbul University Press. All rights reserved.en_US
dc.description.sponsorshipTürkiye Bilimsel ve Teknolojik Araştırma Kurumu, TÜBİTAK: 106S112en_US
dc.description.sponsorshipFinancial Disclosure: This work was supported by the Scientific and Technological Research Council of Turkey (TUBİTAK, Project No: 106S112).en_US
dc.identifier.doi10.26650/experimed.2021.993743
dc.identifier.endpage188en_US
dc.identifier.issn2667-5846
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85173927523en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage184en_US
dc.identifier.urihttps://doi.org/10.26650/experimed.2021.993743
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4178
dc.identifier.volume11en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherIstanbul University Pressen_US
dc.relation.ispartofExperimeden_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAlternative Splicingen_US
dc.subjectLef1en_US
dc.subjectLeukemiaen_US
dc.subjectLymphoiden_US
dc.subjectMyeloiden_US
dc.titleDifferential Expression of LEF1 Isoforms in Adult Lymphoid and Myeloid Malignanciesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu